Premium
Survival analysis of one versus two treatments of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma
Author(s) -
Mehl M. L.,
Seguin B.,
Dernell W. S.,
Lafferty M.,
Kass P. H.,
Withrow S. J.
Publication year - 2005
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5810.2005.00072.x
Subject(s) - medicine , amputation , osteosarcoma , cisplatin , surgery , medical record , chemotherapy , pathology
The purpose of this study was to evaluate one versus two doses of local delivery cisplatin in a biodegradable polymer (OPLA‐Pt) for the treatment of osteosarcoma (OSA) after amputation in dogs. Medical records were reviewed retrospectively, and 105 dogs were included in the study; 39% of dogs received one treatment (surgical implantation) of OPLA‐Pt and 61% of dogs received two treatments of OPLA‐Pt after amputation. Administration of two doses of OPLA‐Pt did not have a significant effect on disease‐free interval or survival time compared to one dose. The anatomic site of the tumour was identified as a prognostic factor, and dogs with proximal humeral OSA had the shortest disease‐free interval and survival times. There was no advantage to giving a second dose of local delivery cisplatin following amputation for the treatment of OSA in dogs.